Retinal Vein Occlusion News and Research

RSS
Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the elderly or middle-aged, it causes a subacute loss of vision.
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Kala Pharmaceuticals completes $22.5 million Series B financing

Kala Pharmaceuticals completes $22.5 million Series B financing

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

New laser provides better treatment for eye diseases in diabetes patients

New laser provides better treatment for eye diseases in diabetes patients

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron fourth quarter total revenues increase to $415 million

Regeneron fourth quarter total revenues increase to $415 million

Thickening of arterial walls causes branch retinal vein occlusion

Thickening of arterial walls causes branch retinal vein occlusion

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

EC approves Regeneron’s EYLEA for treatment of wet AMD

EC approves Regeneron’s EYLEA for treatment of wet AMD

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Lucentis receives FDA approval for treatment of diabetic macular edema

Lucentis receives FDA approval for treatment of diabetic macular edema

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Australian TGA approves Bayer's EYLEA for treatment of wet AMD